Latest News

Sienna Increases European Presence Expanding into Finland with hTERT test
06-Feb-2020

Sienna Increases European Presence Expanding into Finland with hTERT test. Sienna Cancer Diagnos.. READ MORE

Sienna makes first appointment to Clinical Advisory Board
30-Jan-2020

Sienna Cancer Diagnostics Ltd (ASX:SDX), is pleased to announce the appointment of Dr Raoul Con.. READ MORE

hTERT Clinical Study Initiated in Korea
24-Jan-2020

The study, led by Associate Professor of Pathology - Han Suk Ryu and his team from Seoul Nationa.. READ MORE

Investor Information

Sienna is a public listed company headquartered in Melbourne, Australia. In August 2017, Sienna listed on the Australian Securities Exchange under the ticker symbol SDX. The company is governed by an experienced board and management team. Sienna has benefited from over $7.4M in R&D Tax Incentive refunds and government grant programs, significantly bolstering investor contributions and facilitating the progress and growth to date. READ MORE

 

Research

Sienna’s core activities have historically focused on the clinical translation of biomarkers using novel diagnostic technologies for applications in pathology laboratories. The development of inexpensive, high performing in vitro diagnostic tests is expected to lead to radical changes in the approach to care and assessment of cancer patients – a change welcomed by clinicians and governments.  READ MORE

 

About Sienna

Sienna is a medical technology company focussed on the development and commercialisation of novel IVD (in vitro diagnostic) tests. Sienna manufactures IVD products for pathology laboratories to use in their menu of testing services. READ MORE

Contact Sienna

Sienna Cancer Diagnostics

1 Dalmore Drive Scoresby VIC 3179 Australia

Telephone +61 3 8288 2141 Facsimile +61 3 8288 2059